Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is denosumab a safe and effective treatment for postmenopausal osteoporosis?

Nature Clinical Practice Endocrinology & Metabolism volume 4, pages 376–377 (2008)Cite this article

Lewiecki EM et al. (2007) Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 22: 1832–1841

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Simonet WS et al. (1997) Osteoprotegrin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309–319

    Article  CAS  Google Scholar 

  2. Schwarz EM and Ritchlin CT (2007) Clinical development of anti-RANKL therapy. Arthritis Res Ther 9 (Suppl 1): S7

    Article  Google Scholar 

  3. McClung MR et al. (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354: 821–831

    Article  CAS  Google Scholar 

  4. Favus MJ (2006) Does denosumab improve low BMD in postmenopausal women? Nat Clin Pract Endocrinol Metab 2: 600–601

    Article  Google Scholar 

  5. Schwartzman J and Yazici Y (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354: 2390–2391; author reply 2390–2391

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Department of Endocrinology, Diabetes and Metabolism, Brigham and Women's Hospital, 221 Longwood Avenue, Boston, MA 02115, USA keackerman@partners.org

Authors and Affiliations

  1. KE Ackerman is a Clinical Fellow in the Department of Endocrinology, Diabetes and Metabolism, Brigham and Women's Hospital, Boston, MA, USA.,

    Kathryn E Ackerman

Authors
  1. Kathryn E Ackerman
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ackerman, K. Is denosumab a safe and effective treatment for postmenopausal osteoporosis?. Nat Rev Endocrinol 4, 376–377 (2008). https://doi.org/10.1038/ncpendmet0845

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0845

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing